Efeitos da semaglutida em pacientes com insuficiência cardíaca com fração de ejeção preservada e obesidade para controle de sintomas cardiometabólicos: uma revisão de escopo

Abstract

Abstract

Objective: To conduct a scoping review of the efficacy of Semaglutide in patients with Obesity and Heart Failure with Preserved Ejection Fraction as a therapeutic approach in the treatment of cardiometabolic disorders. Method: The Population, Context, Concept (PCC) methodology was used to guide the development of the problem question, using the PubMed, Cochrane, Embase, Epistemonikos and LILACS databases. In the search strategy, Boolean operators and the MeSH/DECS descriptors “Semaglutide”, “Heart Failure”, “Congestive Heart Failure”, “Myocardial Failure”, “Preserved Ejection Fraction”, “Heart Failure, Diastolic”, “Obesity”, “Cardiometabolic Disorders” were used. Results: Eleven studies published between 2020 and 2024 were included, the majority of which were conducted in the USA (72.72%). Data analysis allowed us to evaluate the efficacy of semaglutide on cardiometabolic symptoms in patients with heart failure with preserved ejection fraction and obesity. The results showed significant improvements in patients' quality of life, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12), weight loss and reduction of inflammatory markers. Conclusion: Semaglutide has been shown to be effective in controlling cardiometabolic symptoms in patients with obesity and HFpEF. However, despite the promising results, long-term studies are needed to assess the continued efficacy of semaglutide and more robust data to confirm these findings.